GaBI Journal-Generics and Biosimilars Initiative Journal

metrics 2024

Connecting Professionals in Pharmaceutical Science

Introduction

GaBI Journal - Generics and Biosimilars Initiative Journal, published by PRO PHARMA COMMUNICATIONS INT, serves as a pivotal platform for the dissemination of research and developments in the field of generics and biosimilars. Since its inception in 2014, this journal has established itself as an essential resource for healthcare professionals, researchers, and students dedicated to understanding the complexities of drug regulation and therapeutic equivalence. With an impressive recognition in the Scopus rankings—placing #2 out of 5 in Drug Guides and #20 out of 45 in Pharmacy—it is focused on fostering innovation and enhancing pharmaceutical practices. The journal is indexed with a current impact factor that reflects its significant contributions to the literature, making it a vital reference for those seeking to make advancements in pharmaceutical sciences. While currently not an open-access journal, it aims to support ongoing educational and professional growth in a rapidly evolving industry, ensuring that readers stay informed on the latest developments and research in generics and biosimilars.

Metrics 2024

SCIMAGO Journal Rank0.16
Journal Impact Factor0.30
Journal Impact Factor (5 years)0.60
H-Index15
Journal IF Without Self0.30
Eigen Factor0.00
Normal Eigen Factor0.02
Influence0.14
Immediacy Index-
Cited Half Life-
Citing Half Life-
JCI0.16
Total Documents251
WOS Total Citations75
SCIMAGO Total Citations614
SCIMAGO SELF Citations145
Scopus Journal Rank0.16
Cites / Document (2 Years)0.00
Cites / Document (3 Years)0.86
Cites / Document (4 Years)0.72

Metrics History

Rank 2024

Scopus

Drug Guides in Medicine
Rank #2/5
Percentile 60.00
Quartile Q2
Pharmacy in Health Professions
Rank #20/45
Percentile 55.56
Quartile Q2

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 344/354
Percentile 3.00
Quartile Q4

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 327/354
Percentile 7.63
Quartile Q4

Quartile History

Similar Journals

Journal of Pharmaceutical Policy and Practice

Fostering collaboration for impactful pharmaceutical solutions.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Journal of Pharmaceutical Policy and Practice, published by Taylor & Francis Ltd, is a premier open access journal dedicated to advancing the field of pharmaceutical policy and practice. Launched in 2013, this esteemed journal has rapidly become a vital resource for researchers, practitioners, and policymakers alike, offering a critical examination of health policies and their implementation in pharmaceutical contexts. With an impressive impact factor reflecting its significance, it ranks in the Q2 category for Health Policy and Q1 in both Pharmacology, Toxicology and Pharmaceutics and Pharmacy, showcasing its high-quality contributions to the field. Accessible to a global audience since 2014, the journal disseminates innovative research findings that inform best practices, foster policy development, and enhance patient outcomes in the pharmaceutical landscape. Positioned in the UK and with strong Scopus rankings, specifically ranked #3 in Health Professions (Pharmacy), the journal serves as an essential platform for those striving to navigate the ever-evolving intersection of healthcare and pharmaceutical sciences.

International Journal of Clinical Pharmacy

Empowering Healthcare through Innovative Pharmaceutical Research
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya

Empowering researchers with open access to vital findings.
Publisher: PYATIGORSKII MEDIKO-FARMATSEVTICHESKII INSTISSN: 2307-9266Frequency: 6 issues/year

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Exploring the frontiers of clinical pharmacy and therapeutics.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

Clinical Pharmacology-Advances and Applications

Bridging Research and Practice in Pharmacology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

AMERICAN JOURNAL OF THERAPEUTICS

Advancing Therapeutic Knowledge for a Healthier Tomorrow
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1075-2765Frequency: 6 issues/year

The American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.

Cyprus Journal of Medical Sciences

Fostering a deeper understanding of healthcare challenges.
Publisher: GALENOS PUBL HOUSEISSN: 2149-7893Frequency: 6 issues/year

Welcome to the Cyprus Journal of Medical Sciences, a distinguished publication dedicated to the advancement of medical knowledge and research. Published by GALENOS PUBL HOUSE, this journal endeavors to uphold the highest standards of scientific inquiry in the medical field. With its ISSN 2149-7893 and E-ISSN 2536-507X, the journal serves as an essential resource for researchers, healthcare professionals, and students seeking to stay abreast of innovative findings and clinical practices. Although currently not listed under Open Access, this journal prioritizes rigorous peer review and the dissemination of impactful research aimed at driving improvements in medical science. The journal welcomes submissions that cover diverse areas within the medical realm, contributing to a more profound understanding of healthcare challenges and solutions. Join us in exploring the frontiers of medical sciences and contributing to a healthier future.

Journal of Pioneering Medical Sciences

Empowering global health through open access research.
Publisher: JPMS PUBLISSN: 2309-7981Frequency: 4 issues/year

Journal of Pioneering Medical Sciences, published by JPMS PUBL in Karachi, Pakistan, stands as a vital resource in the field of medical research and practice. Established in 2012, this Open Access journal fosters the dissemination of innovative findings and groundbreaking studies that contribute to the advancement of medical science. With an ISSN of 2309-7981 and a commitment to rigorous peer-review, the journal encompasses a diverse range of topics, aiming to bridge knowledge gaps and promote interdisciplinary dialogue among healthcare professionals and researchers. Although it currently lacks an H-index, its focus on pioneering medical studies positions it as a platform for impactful contributions that can shape future healthcare policies and practices. The journal's open access policy ensures that vital research is freely available to a global audience, promoting accessibility and collaboration in the medical community.

BIODRUGS

Elevating Research Standards in Biopharmaceuticals
Publisher: ADIS INT LTDISSN: 1173-8804Frequency: 6 issues/year

BIODRUGS is a prestigious academic journal published by ADIS INT LTD, specializing in the rapidly evolving fields of biotechnology, pharmacology, and medicine. Since its inception in 1997, this journal has established itself as a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address both fundamental and clinical aspects of biopharmaceuticals. With an impressive impact factor and categorized within the prestigious Q1 quartile across multiple disciplines, including pharmacology and biotechnology, BIODRUGS ranks among the top in its field, reflecting its significant contributions to advancing knowledge. The journal's commitment to providing open access facilitates broad dissemination of its content, ensuring that researchers, professionals, and students can easily access critical insights and novel findings. The journal's scope extends well into 2024 and beyond, promising ongoing relevance and a continuous source of insightful academic discourse.

THERAPEUTIC DRUG MONITORING

Pioneering the Future of Therapeutic Drug Management
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0163-4356Frequency: 6 issues/year

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.